ES502549A0 - Procedimiento para aislar antigenos glicoproteicos de un vi-rus - Google Patents

Procedimiento para aislar antigenos glicoproteicos de un vi-rus

Info

Publication number
ES502549A0
ES502549A0 ES502549A ES502549A ES502549A0 ES 502549 A0 ES502549 A0 ES 502549A0 ES 502549 A ES502549 A ES 502549A ES 502549 A ES502549 A ES 502549A ES 502549 A0 ES502549 A0 ES 502549A0
Authority
ES
Spain
Prior art keywords
rus
isolating
procedure
glycoproteic
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES502549A
Other languages
English (en)
Other versions
ES8203225A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Publication of ES502549A0 publication Critical patent/ES502549A0/es
Publication of ES8203225A1 publication Critical patent/ES8203225A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES502549A 1980-06-05 1981-05-27 Procedimiento para aislar antigenos glicoproteicos de un vi-rus Expired ES8203225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8012522A FR2483779A1 (fr) 1980-06-05 1980-06-05 Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins

Publications (2)

Publication Number Publication Date
ES502549A0 true ES502549A0 (es) 1982-04-01
ES8203225A1 ES8203225A1 (es) 1982-04-01

Family

ID=9242745

Family Applications (1)

Application Number Title Priority Date Filing Date
ES502549A Expired ES8203225A1 (es) 1980-06-05 1981-05-27 Procedimiento para aislar antigenos glicoproteicos de un vi-rus

Country Status (19)

Country Link
US (1) US4344935A (es)
EP (1) EP0041880B1 (es)
JP (1) JPS5726624A (es)
AR (1) AR228865A1 (es)
AT (1) ATE3239T1 (es)
AU (1) AU546088B2 (es)
CA (1) CA1174598A (es)
DE (1) DE3160264D1 (es)
DK (1) DK228081A (es)
ES (1) ES8203225A1 (es)
FI (1) FI811685L (es)
FR (1) FR2483779A1 (es)
GR (1) GR74610B (es)
IE (1) IE51226B1 (es)
IL (1) IL62913A (es)
NO (1) NO811873L (es)
NZ (1) NZ197306A (es)
PT (1) PT73032B (es)
ZA (1) ZA813479B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721675A (en) * 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
US4645666A (en) * 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
GB8502096D0 (en) * 1985-01-28 1985-02-27 Medical Res Council Influenza vaccine
NZ224422A (en) * 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
US4975119A (en) * 1989-04-25 1990-12-04 Rheox, Inc. Liquid antisettling agents for organic coating compositions
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
US5741493A (en) * 1991-01-24 1998-04-21 Pasteur Merieux Serums Et Vaccins Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
US6780630B1 (en) * 1992-07-10 2004-08-24 Baylor College Of Medicine Parenteral immunization against rotavirus
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
EP0833670B1 (en) 1995-06-14 2003-09-03 Baylor College Of Medicine Vaccine against rotavirus infection comprising peptides of viral enterotoxin nsp4
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
DE19938767C2 (de) * 1999-08-16 2002-10-24 Tad Pharma Gmbh Spaltimpfstoffe

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE661402A (es) 1964-03-20
US3847737A (en) * 1965-03-22 1974-11-12 A Kanarek Inactivation of myxoviruses and method of preparing a vaccine therefrom
US3629470A (en) * 1968-04-08 1971-12-21 Burroughs Wellcome Co Process for purification of animal rna viruses
BR6915288D0 (pt) * 1969-03-15 1973-02-08 Bayer Ag Processo para a purificacao de solucoes do virus da febre aftosa
US3989818A (en) * 1970-08-14 1976-11-02 South African Inventions Development Corporation Influenza virus vaccine
US3790552A (en) * 1972-03-16 1974-02-05 Us Health Method of removing hepatitis-associated antigen from a protein fraction using polyethylene glycol
US3962421A (en) * 1973-06-18 1976-06-08 American Home Products Corporation Method for the disruption of lipid-containing viruses
GB1486557A (en) 1973-10-18 1977-09-21 Flockhart & Co Process for the preparation of pyrogen-free sub-unit vaccine
US3951937A (en) * 1973-12-20 1976-04-20 The Community Blood Council Of Greater New York, Inc. Large scale purification of hepatitis type B antigen using polyethylene glycol
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
AU507149B2 (en) 1975-01-16 1980-02-07 Mount Sinai School Of Medicine Of The City University Of New York, The Method of influenza immunization
FR2422720A2 (fr) 1977-04-26 1979-11-09 Elf Aquitaine Separation et purification de proteines par chromatographie
FI66020C (fi) * 1977-09-19 1984-08-10 Merck & Co Inc Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2
DE2750045A1 (de) * 1977-11-09 1979-05-10 Behringwerke Ag Verfahren zur entfernung von detergentien aus virusantigensuspensionen

Also Published As

Publication number Publication date
ES8203225A1 (es) 1982-04-01
CA1174598A (en) 1984-09-18
PT73032B (fr) 1982-07-01
FR2483779A1 (fr) 1981-12-11
IL62913A0 (en) 1981-07-31
IL62913A (en) 1984-08-31
EP0041880B1 (fr) 1983-05-11
NO811873L (no) 1981-12-07
IE51226B1 (en) 1986-11-12
EP0041880A1 (fr) 1981-12-16
ATE3239T1 (de) 1983-05-15
DE3160264D1 (en) 1983-06-16
DK228081A (da) 1981-12-06
ZA813479B (en) 1982-06-30
AU546088B2 (en) 1985-08-15
AU7117081A (en) 1981-12-10
GR74610B (es) 1984-06-29
NZ197306A (en) 1984-03-16
FR2483779B1 (es) 1983-07-22
AR228865A1 (es) 1983-04-29
JPS5726624A (en) 1982-02-12
IE811168L (en) 1981-12-05
FI811685L (fi) 1981-12-06
US4344935A (en) 1982-08-17
PT73032A (fr) 1981-06-01

Similar Documents

Publication Publication Date Title
ES499171A0 (es) Un procedimiento para preparar antibioticos de beta-lactama
ES501139A0 (es) Un procedimiento para la obtencion de microcapsulas
ES505517A0 (es) Un procedimiento para la preparacion de un derivado de n- arilbenzamida
ES500726A0 (es) Un procedimiento para preparar diaminopiridinas
ES528000A0 (es) Un procedimiento para la purificacion de un antigeno.
ES506141A0 (es) Un procedimiento para la preparacion de piridin- y pira- cin-derivados
ES500727A0 (es) Un procedimiento para preparar imidazo-piridinas
ES502549A0 (es) Procedimiento para aislar antigenos glicoproteicos de un vi-rus
ES503134A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES267169Y (es) Brida para acoplamiento de elementos estructurales tubulare
ES505498A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES504764A0 (es) Un procedimiento para la preparacion de un derivado 2-tiope-nem
ES502180A0 (es) Procedimiento para la obtencion de un nuevo antiacido gas- trico
ES501571A0 (es) Un procedimiento para la preparacion de aminas terciarias
ES521361A0 (es) Un metodo para preparar un derivado 14-acilico de lankacidina.
ES504376A0 (es) Un procedimiento para la preparacion de un derivado de fene-tilamina
ES501232A0 (es) Un procedimiento para la preparacion de fenil-quinolicidinas
ES500776A0 (es) Un procedimiento para preparar un adhesivo
ES500464A0 (es) Un procedimiento para preparar 2-halogeno-acetanilidas
ES505886A0 (es) Un procedimiento para obtener nuevos compuestos de beta-lac-tama
ES499558A0 (es) Un procedimiento para preparacion de nuevas piperidinoquinazolinas.
AR229035A1 (es) Metodo para la preparacion de un derivado 2-n-metilol de cefalexina
ES505714A0 (es) Un procedimiento para preparar compuestos de cefem
ES501277A0 (es) Un procedimiento para la preparacion de perfluoroamidas
ES520407A0 (es) Un procedimiento para preparar un derivado de 3-azetidiniletil-1-fenil-2-imidazolidinona.